The FDA’s approval of CTLA-4, PD-1, and PD-L1 antibodies underscores the therapeutic potential of a deeper understanding of co-inhibitory pathways, with agonistic antibodies for autoimmune diseases showing promise. This evidence concerns the gene CTLA4 and autoimmune disease.